Prelude Therapeutics Valuation
| PRLD Stock | USD 2.24 0.15 7.18% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Prelude Therapeutics holds a recent Real Value of $2.58 per share. The prevailing price of the company is $2.24. Our model determines the value of Prelude Therapeutics from analyzing the company fundamentals such as Shares Owned By Insiders of 9.93 %, return on equity of -1.04, and Current Valuation of 93.97 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Prelude Therapeutics' valuation include:
Price Book 2.2393 | Enterprise Value | Enterprise Value Ebitda (0.54) | Price Sales 12.5132 | Enterprise Value Revenue 8.9496 |
Undervalued
Today
Please note that Prelude Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Prelude Therapeutics is based on 3 months time horizon. Increasing Prelude Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Prelude stock is determined by what a typical buyer is willing to pay for full or partial control of Prelude Therapeutics. Since Prelude Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Prelude Stock. However, Prelude Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.24 | Real 2.58 | Target 4.0 | Hype 2.27 |
The real value of Prelude Stock, also known as its intrinsic value, is the underlying worth of Prelude Therapeutics Company, which is reflected in its stock price. It is based on Prelude Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Prelude Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Prelude Therapeutics helps investors to forecast how Prelude stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Prelude Therapeutics more accurately as focusing exclusively on Prelude Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Prelude Therapeutics' intrinsic value based on its ongoing forecasts of Prelude Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Prelude Therapeutics' closest peers. If more than one evaluation category is relevant for Prelude Therapeutics we suggest using both methods to arrive at a better estimate.
Prelude Therapeutics Cash |
|
Prelude Therapeutics Total Value Analysis
Prelude Therapeutics is at this time expected to have valuation of 93.97 M with market capitalization of 131.39 M, debt of 18.02 M, and cash on hands of 246.3 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Prelude Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
93.97 M | 131.39 M | 18.02 M | 246.3 M |
Prelude Therapeutics Investor Information
About 55.0% of the company shares are owned by institutional investors. The book value of Prelude Therapeutics was at this time reported as 0.77. The company recorded a loss per share of 1.47. Prelude Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Prelude Therapeutics' liquidity, profitability, solvency, and operating efficiency, Prelude Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Prelude Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Prelude Therapeutics has an asset utilization ratio of 3.99 percent. This indicates that the Company is making $0.0399 for each dollar of assets. An increasing asset utilization means that Prelude Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Prelude Therapeutics Profitability Analysis
Based on Prelude Therapeutics' profitability indicators, Prelude Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Prelude Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-03-31 | Previous Quarter -31.2 M | Current Value -19.7 M | Quarterly Volatility 9.7 M |
For Prelude Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Prelude Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Prelude Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Prelude Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Prelude Therapeutics over time as well as its relative position and ranking within its peers.
Prelude Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Prelude Therapeutics is estimated to be -0.28 with future projections ranging from a low of -0.3 to a high of -0.26. Prelude Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -1.47. Please be aware that the consensus of earnings estimates for Prelude Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Prelude Therapeutics Earnings Estimation Breakdown
The calculation of Prelude Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Prelude Therapeutics is estimated to be -0.28 with the future projection ranging from a low of -0.3 to a high of -0.26. Please be aware that this consensus of annual earnings estimates for Prelude Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.3 Lowest | Expected EPS | -0.26 Highest |
Prelude Therapeutics Earnings Projection Consensus
Suppose the current estimates of Prelude Therapeutics' value are higher than the current market price of the Prelude Therapeutics stock. In this case, investors may conclude that Prelude Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Prelude Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 3 | 53.9% | 0.0 | -0.28 | -1.47 |
Prelude Therapeutics Ownership Allocation
Prelude Therapeutics owns a total of 43.77 Million outstanding shares. Over half of Prelude Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Prelude Therapeutics Profitability Analysis
The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 10.5 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Prelude Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Prelude Therapeutics and how it compares across the competition.
About Prelude Therapeutics Valuation
The stock valuation mechanism determines Prelude Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Prelude Therapeutics. We calculate exposure to Prelude Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Prelude Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 8.1 M | 8.5 M | |
| Pretax Profit Margin | (16.35) | (17.17) | |
| Operating Profit Margin | (17.96) | (18.86) | |
| Net Loss | (16.35) | (17.17) |
Prelude Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Prelude Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Prelude we look at many different elements of the entity such as Prelude's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Prelude Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Prelude Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Prelude Therapeutics' worth.Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges |